Clinical trial of flupentixol and melitracen tablets in the treatment of cerebral infarction with anxiety disorder
10.13699/j.cnki.1001-6821.2018.07.004
- VernacularTitle:氟哌噻吨美利曲辛片治疗脑梗死伴焦虑症的临床研究
- Author:
Fa-Qiang LI
1
;
Ai-Ling JI
;
Ti-Jun DAI
Author Information
1. 徐州市肿瘤医院神经内科
- Keywords:
flupentixol and melitracen tablet;
psychological intervention;
cerebral infarction;
anxiety disorder
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(7):750-752
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of flupentixol and melitracen tablets combined with psychological intervention in the treatment of cerebral infarction with anxiety disorder.Methods Eighty patients with cerebral infarction and anxiety disorders were randomly divided into control group and treatment group with 40 cases per group.Control group was treated with antiplatelet aggregation,activating blood stasis and brain protectant and so on.Treatment group was treated with flupentixol and melitracen tablet 10 mg per group,bid,orally,and psychological intervention once every 3-5 days,on the basis of control group.Two groups were treated for 6 weeks.The self rating scale (SAS)scores,depression self rating scale (SDS) scores,the United States national institutes of health stroke scale (NIHSS) scores and adverse drug reactions were compared between two groups.Results After treatment,the main indexes in treatment and control groups were compared:SAS scores were (40.07 ± 3.02) and (52.07 ± 6.94) points,SDS scores were (40.03 ±3.38) and (51.48 ± 7.22) points,NIHSS scores were (6.04 ± 1.51) and (8.92 ± 4.12) points,the differences were statistically significant (all P ＜ 0.05).No adverse drug reactions in two groups occurred during the treatment.Conclusion Flupentixol and melitracen tablets combined with psychological intervention have a definitive clinical efficacy and safety in the treatment of cerebral infarction with anxiety disorder,which can significantly reduce the NIHSS scores and improve prognosis.
